Ph2/3 Study of livmoniplimab in combo with budigalimab in untreated metastatic NSCLC (LIVIGNO-4)
Phase II/III Clinical Trial
A Randomized Phase 2/3 Study to Evaluate the Optimal Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - LIVIGNO-4 (M23-721)